Cipla gets USFDA nod for Paclitaxel Protein bound Particles for Injectable Suspension Ruchika Sharma11 April 2025 11:30 AM ISTMumbai: Cipla has announced that the Company has received final approval from the United States Food and Drug Administration (USFDA) for the ...
GSK gets European Commission nod for expanded use of Jemperli in endometrial cancer Ruchika Sharma21 Jan 2025 1:30 PM ISTLondon: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy...
Merck gets positive EU CHMP opinions for Keytruda regimens for patients with two types of Gynecologic cancers Ruchika Sharma24 Sept 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's Committee for Medicinal...
US FDA expands Jemperli plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer: GSK Ruchika Sharma2 Aug 2024 10:00 AM ISTLondon: GSK plc has announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and...
USFDA approves Merck Keytruda plus Carboplatin, Paclitaxel for Primary Advanced or Recurrent Endometrial Carcinoma Ruchika Sharma18 Jun 2024 11:30 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has approved...
AstraZeneca Imfinzi plus chemotherapy gets USFDA nod for mismatch repair deficient advanced or recurrent endometrial cancer Ruchika Sharma17 Jun 2024 11:30 AM ISTCambridge: AstraZeneca has announced that Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy has...
GSK application for expanded indication of Jemperli plus chemotherapy accepted by USFDA for priority review Ruchika Sharma25 April 2024 12:40 PM ISTLondon: GSK plc has announced the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for...
Merck application for Keytruda plus chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma accepted by USFDA for priority review Ruchika Sharma22 Feb 2024 12:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has accepted for...
Jemperli plus Zejula combo significantly improved progression-free survival in primary advanced or recurrent endometrial cancer: GSK Ruchika Sharma20 Dec 2023 2:30 PM ISTLondon: GSK plc has announced positive headline results from a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial...
Phase III trial of Jemperli plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer: GSK Ruchika Sharma31 Oct 2023 11:35 AM ISTLondon: GSK plc has announced positive headline results from a planned analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial...
GSK gets USFDA nod for Jemperli plus chemotherapy for dMMR/MSI-H primary advanced or recurrent endometrial cancer Ruchika Sharma1 Aug 2023 11:30 AM ISTJemperli is already approved in the US as monotherapy in adult patients with dMMR recurrent or advanced endometrial cancer that has progressed on or...
Intraperitoneal carboplatin could be used as first-line treatment in ovarian cancer Aditi28 April 2023 9:30 AM ISTJapan: An ORIGINAL ARTICLE entitled "Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial" written by Nagao et al. has mentioned the...
